HIMS HERS HEALTH INC CLASS A (HIMS)
Health Care · digital health / telehealth · NYSE
A consumer-first digital health platform transforming the fulfillment of healthcare services and wellness products through an integrated telehealth and pharmacy model.
What HIMS HERS HEALTH INC CLASS A does
Hims & Hers Health is a digital health platform that connects consumers with licensed healthcare professionals to provide personalized treatments and wellness products. Its platform integrates a provider network, electronic medical records, digital prescriptions, and cloud-enabled pharmacy fulfillment. The company focuses on conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health.
Themes: telehealth, e-commerce pharmacy, personalized medicine, weight loss drugs, digital health platform
Fundamentals
- Price$33.78 as of 2026-08-21 close
- Market cap$6.7B as of 2026-08-24
- 1-year return-23.2% 2025-08-21 close $43.96 → 2026-08-21 close $33.78
- P/E52.29 as of 2026-08-24
- Net margin-0.6% as of 2026-08-24
- Gross margin+72.9% as of 2026-08-24
- ROE-2.5% as of 2026-08-24
- Debt / equity2.18 as of 2026-08-24
- Revenue growth (YoY)+32.8% as of 2026-08-24
- Revenue CAGR (3y)+64.5% SEC XBRL
- Beta2.47 as of 2026-08-24
- Last reported earnings2026-08-10 SEC EDGAR Form 8-K (Item 2.02)
How HIMS compares in its sector
- price-to-earnings ratiotop 25% 203 covered Health Care peers, as of 2026-08-24
- net profit marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- operating marginmiddle range 504 covered Health Care peers, as of 2026-08-24
- gross marginmiddle range 384 covered Health Care peers, as of 2026-08-24
- return on equitymiddle range 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRtop 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
HIMS is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
52.2 #655 of 1,704 scored · #118 of 240 in Health Care
Catalysts 65th: the analyst consensus rating has improved toward "buy" since the prior reading; setup 64th: day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it); weakest is trend 58th: a "golden cross" — its 50-day average is above its 200-day. Its score is docked 10 points for overextended (RSI above 75 or stochastic above 90).
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How HIMS HERS HEALTH INC CLASS A looks technically
HIMS HERS HEALTH INC CLASS A (HIMS) is trading 14.9% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 13 trading days ago — a "golden cross", a bullish long-term signal. There is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend). Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive). It just made a new 20-day high, its first since 2026-07-15, pushing above its recent trading range. It is 48.3% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 14.9% above its 200-day average, the long-term trend line — a longer-term uptrend | +14.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $32.03 | $32.03 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $29.41 | $29.41 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 16 calendar days ago — the swings before that are what the structure reading is measured on | 16 sessions |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 13 trading days ago — a "golden cross", a bullish long-term signal | 13 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 14.9% above | +14.9% |
| Trend strength (14-day ADX) | there is no clear trend right now — the price is choppy (ADX, a 0–100 trend-strength gauge, is 14, below the 25 that marks a real trend) | 14.4 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.2 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($27.38 to $34.46) — its "stochastic" reading is 90 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 90.5 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bullish about 2 trading days ago (its momentum flipped positive) | 2 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $65.30 | $65.30 |
|---|---|---|
| From the 52-week high | it is 48.3% below its 52-week high (its highest price of the past year) | -48.3% |
| Above the 52-week low | it is 145.9% above its 52-week low (its lowest price of the past year) | +145.8% |
| Below the 52-week high | it is 48.3% below its highest point of the past year | 48.3% |
| Since a 20-day breakout | it just made a new 20-day high, its first since 2026-07-15, pushing above its recent trading range | 1 session |
| Since a 55-day breakout | it made a new 55-day high about 35 trading days ago | 35 sessions |
| All-time high | its highest closing price on record is $72.98 (set on 2025-02-19) | $72.98 |
| Given back of the 52-week move | over the past year its closes ranged ($14.52 to $62.76), and it has recovered roughly a third of its fall from last year’s high — 40% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $44.33 to $45.88. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 39.9% |
| From the all-time high | it is 53.7% below its all-time high | -53.7% |
| Nearest price level | it is trading 3.4% above a support level at $32.65 — a price it turned at twice since 2025-11-21, most recently on 2026-08-05. Since 2024-08-21 it has 3 such levels below the current price and 7 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -3.4% |
| All-time low | its lowest closing price on record is $2.72 (set on 2022-05-12) | $2.72 |
| Above the all-time low | it is 1141.9% above its all-time low | +1,142% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are narrower than usual versus its own recent 6-month history (tighter than about 86% of it) | 14th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.36 between its high and its low — about 7.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.36 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $25.72 and $33.99 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $25.72 – $29.86 – $33.99 |
| Typical daily range (% of price) | its price moves about 7.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 7.0% |
| Stretch from the 200-day average | it is trading 1.9 daily ranges above its 200-day average price (14.9% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 1.9 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.02× |
|---|
Analyst
2
| Change in the average price target | analysts have cut their average price target by 1.0% since the prior reading | -1.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating has improved toward "buy" since the prior reading | 0.07 toward buy |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.6% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | -0.6% |
|---|---|---|
| Open gap | it gapped 2.6% above the previous close 57 sessions ago and has not traded back through the level it left behind at 23.85 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.6% |
| Gap filled | a 2.7% gap down opened on 2026-08-18 has been "filled" 3 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 3 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 3 sessions in a row, a +23.33% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 3 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 0.9 percentage points (the stock gained 3.2% while the market gained 2.3%) | +0.9% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 37.6 percentage points (the stock gained 40.7% while the market gained 3.1%) | +37.6% |
| vs market, 6 months | over the past 6 months this stock beat the market by 105.1 percentage points (the stock gained 116.1% while the market gained 11.1%) | +105.1% |
| vs market, 12 months | over the past 12 months this stock lagged the market by 43.6 percentage points (the stock lost 23.2% while the market gained 20.5%) | -43.6% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, a fresh 20-day high, MACD momentum is positive, outperforming the market over 6 months — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 1 of the 9 technical signals we can compute for it is currently in a bearish state: near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 1 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading inside the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the zone traders read as unresolved — neither side has established a trend, and the band is where that gets settled. The band itself is thick, spanning 11.5% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | 0.0% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 33% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $25.38 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +33.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 10% above the average price paid since it last reported on 2026-08-10 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $30.58 — a volume-weighted average of daily closes over 10 sessions, not a true tick-by-tick VWAP. | +10.5% |
Price levels it has turned at before
HIMS last closed at $33.78 on 2026-08-21. Since 2024-08-21 it has turned at 3 prices below its last close and 7 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $32.65 | Support | 3.4% below the last close | turned there twice · 2025-11-21 to 2026-08-05 |
| $36.06 | Resistance | 6.8% above the last close | turned there four times · 2025-02-25 to 2026-06-22 |
| $30.26 | Support | 10.4% below the last close | turned there four times · 2024-11-13 to 2026-06-25 |
| $38.87 | Resistance | 15.1% above the last close | turned there twice · 2025-03-25 to 2026-07-06 |
| $40.90 | Resistance | 21.1% above the last close | turned there four times · 2025-06-26 to 2025-12-05 |
| $24.03 | Support | 28.9% below the last close | turned there five times · 2024-10-22 to 2026-07-30 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
No Elliott-wave labelling currently fits its swings: the recent highs and lows do not satisfy the three rules a five-wave count has to obey, so there is no count to show rather than a count we are unsure about.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · Broke out to a new 20-day high · MACD just crossed bullish (12/26/9) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingHold (2.73 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$30.85 range $23.00 – $42.00; median $30.00
Analyst estimates, as of 2026-08-21. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for HIMS
- Consensus EPS estimate$0.09112 next reporting period, as of 2026-08-21
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Dependence on third-party licensed pharmacies and provider networks for operations and compliance.","Regulatory environment related to telehealth and prescription medications is complex and subject to change.","Operating in highly competitive markets with potential for price pressure and shifting consumer demand."]
What changed in the latest 10-Q
AI-assisted comparison of HIMS's 10-Q filed 2026-05-11 against the prior one filed 2025-11-03.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K for year ended December 31, 2025 (newer filing) vs. December 31, 2024 (older filing)
- Description of 'platforms (collectively, our "platform")' and expanded list of conditions treated: 'sexual health, hair loss, hormone health, weight loss, dermatology, and mental health' (newer) vs. 'sexual health, mental health, men's dermatology, women's dermatology, and weight loss' (older)
- Addition of 'United States Revenue' and 'Rest of the World Revenue' as key business metrics in newer filing
- New definition: 'United States Revenue represents the sales of products and services by our consolidated legal entities operating within jurisdictions located inside of the United States'
- New definition: 'Rest of the World Revenue represents the sales of products and services by our consolidated legal entities operating within jurisdictions located outside of the United States'
- Removed:
- Reference to 'Online Revenue and Wholesale Revenue' as the two financial results monitored (replaced with 'United States Revenue and Rest of the World Revenue' in newer filing)
- Specific description of 'Online Revenue' definition removed from this section in newer filing
- Specific description of 'Wholesale Revenue' definition removed from this section in newer filing
- Reference to 'Monthly Online Revenue per Average Subscriber' metric replaced with 'Monthly Revenue per Average Subscriber' in newer filing
- Phrase 'As an example, our management primarily uses' removed; replaced with 'Our management primarily uses'
- Reworded:
- 'technical platform' changed to 'technical infrastructure' in Overview section
- 'The Hims & Hers platform' changed to 'The Hims & Hers platforms (collectively, our "platform")' indicating plural platforms
- Revenue metric definition changed from 'Online Revenue' to consolidated revenue 'primarily comprises online sales of health and wellness products through our websites and mobile applications, including prescription and non-prescription products, as well as services'
- Wholesale revenue explanation moved from separate metric definition to general statement that 'in the United States, we offer a range of health and wellness products through wholesale partners' with such revenue 'not considered material to our business'
- 'Monthly Online Revenue per Average Subscriber' metric renamed to 'Monthly Revenue per Average Subscriber' (removing 'Online' from the name)
- Section header organization: revenue metrics moved from separate 'Online Revenue' and 'Wholesale Revenue' definitions to geographic-based 'United States Revenue' and 'Rest of the World Revenue' definitions
- Notes:
- The newer filing text is truncated at 'The tab' and does not include the complete revenue table that was referenced in the older filing, making a full comparison of the revenue breakdown section impossible
- The older filing text is also truncated and does not show the complete revenue table section
Risk Factors
- Added:
- Added risk factor: 'Acquisitions and investments could result in operating difficulties, dilution, and other harmful consequences that may adversely impact our business, financial condition, and results of operations. Additionally, if we are not able to identify and successfully acquire suitable businesses, our results of operations and prospects could be harmed.' (filed 2026-05-11)
- Added risk factor: 'Expansion into international markets is important for our growth, and as we expand internationally, we will face additional business, political, legal, regulatory, operational, financial, and economic risks, any of which could increase our costs and hinder such growth.' (filed 2026-05-11)
- Added risk factor: 'We have been, and in the future may be, subject to actions and public statements by U.S. federal and state government officials and agencies, which could materially and adversely affect our business, financial condition, results of operations and reputation.' (filed 2026-05-11)
- Added risk factor: 'Disruption to our global supply chain, including as a result of evolving laws and regulations, can impact our operations in ways that may be difficult to predict or control, may require us to modify or discontinue certain supplier relationships, sourcing strategies, or operational processes, and may result in delays in product availability, increased costs for compliance or alternative sourcing, or the need to shift to different third-party partners.' (filed 2026-05-11)
- Removed:
- Removed from Summary of Principal Risk Factors: 'We may not be able to maintain our profitability.' Language changed to 'We may not be able to maintain our profitability in any given period.' (filed 2026-05-11)
- Removed detailed supply chain and regulatory risk language that was previously integrated in the regulated environment risk factor and relocated to a separate risk factor (filed 2026-05-11)
- Removed from risk factor: 'From time to time we are subject to legal proceedings in the ordinary course of business, which can include intellectual property disputes or claims relating to our marketing or sale of products, any of which may be costly to defend and could materially harm our business and results of operations.' Language expanded to include 'legal and regulatory proceedings and inquiries' (filed 2026-05-11)
- Reworded:
- Changed 'We may not be able to maintain our profitability.' to 'We may not be able to maintain our profitability in any given period.' in Summary of Principal Risk Factors (filed 2026-05-11)
- Changed 'The market price of our Class A common stock may be volatile.' to 'The market price of our Class A common stock has been and may continue to be volatile.' in Summary of Principal Risk Factors (filed 2026-05-11)
- Separated and restructured supply chain and regulatory compliance language. Older filing combined supply chain disruption discussion within the regulated environment risk factor; newer filing creates separate risk factor for global supply chain disruptions (filed 2026-05-11)
- Changed 'From time to time we are subject to legal proceedings' to 'From time to time we are subject to legal and regulatory proceedings and inquiries' (filed 2026-05-11)
- Updated financial metrics in detailed risk discussion: newer filing shows revenue growth to $2,347.6 million for year ended December 31, 2025 and 2,442 employees as of December 31, 2025; older filing showed revenue of $1,476.5 million for year ended December 31, 2024 and 1,637 employees as of December 31, 2024 (filed 2026-05-11 vs 2025-11-03)
- Notes:
- The newer filing text provided appears truncated at the end of the 'Risks Related to Our Business' section, limiting complete comparison of the detailed risk discussion paragraphs
- The older filing text also appears truncated at the end of the detailed risk discussion, limiting full comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 8 open-market sales by insiders in the last 90 days.
- Last 90 days0 buys · 8 sells ($4M) — 5 selling insiders
- Last 180 days1 buy ($1M) · 13 sells ($6M) — 1 buying, 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-07-17. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about HIMS's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Congressional trading disclosures
U.S. House members publicly disclose their own, their spouse's, and dependent children's stock transactions under the STOCK Act. We hold 1 matched disclosure for HIMS from U.S. House Clerk Periodic Transaction Report filings.
Congressional trading disclosures →Institutional ownership (13F)
6 institutional 13F filers reported holding HIMS as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 6
- Reported shares held 47,840,267
- Reported value $993,163,938
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 2 increased, 4 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
HIMS had 62,215,733 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
Short interest as a percent of shares outstanding is not shown for HIMS because we do not hold a verified share count to divide it by. The reported figures above are unaffected.
- Reported short interest (shares) 62,215,733
- Prior settlement (shares) 61,410,121
- Reported change 1.31%
- Days to cover (reported) 3.71
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Teladoc Health (TDOC)
- Ro
- Amazon Pharmacy (AMZN)
- CVS Health (CVS)
- Walgreens Boots Alliance (WBA)
- GoodRx Holdings (GDRX)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare HIMS vs…
Frequently asked questions
What does HIMS HERS HEALTH INC CLASS A (HIMS) do?
Hims & Hers Health is a digital health platform that connects consumers with licensed healthcare professionals to provide personalized treatments and wellness products. Its platform integrates a provider network, electronic medical records, digital prescriptions, and cloud-enabled pharmacy fulfillment. The company focuses on conditions including sexual health, hair loss, hormone health, weight loss, dermatology, and mental health.
What sector is HIMS HERS HEALTH INC CLASS A (HIMS) in?
HIMS HERS HEALTH INC CLASS A (HIMS) is classified in the Health Care sector. Its industry is digital health / telehealth. It trades on NYSE.
Who are HIMS HERS HEALTH INC CLASS A's (HIMS) competitors?
Notable peers of HIMS HERS HEALTH INC CLASS A (HIMS) include Teladoc Health, Ro, Amazon Pharmacy, CVS Health and Walgreens Boots Alliance. This peer set is informational only — not financial advice.
Has there been recent Congressional stock trading in HIMS?
Yes — we hold 1 matched STOCK Act disclosure for HIMS from U.S. House Clerk Periodic Transaction Report filings. These are legally-required disclosures (often filed 30–45 days after the trade), may belong to a U.S. House member, their spouse, or a dependent child, and are not an indicator of company performance or investment advice.
Is HIMS HERS HEALTH INC CLASS A (HIMS) overbought or oversold right now?
HIMS HERS HEALTH INC CLASS A (HIMS) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on HIMS come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.